Fenix Innovation Group

Researchers are testing a full-spectrum medicinal cannabis extract with very low THC to see if it can reduce the severity of autism spectrum disorder in young people aged 8 to 17. The study compares the extract to a control and then allows some participants to receive it openly. …

Researchers are testing a full-spectrum medicinal cannabis extract called NTI164 in girls and young women with Rett syndrome, a rare genetic disorder that affects movement, speech, and behavior. The study includes 14 participants aged 5 to 20 who take the extract daily for 16 wee…

Researchers are testing a full-spectrum medicinal cannabis extract called NTI164, which contains 0.08% THC, in children with pediatric acute-onset neuropsychiatric syndrome (PANS). PANS causes sudden, severe obsessive-compulsive symptoms, restricted eating, and other psychiatric …

This trial tests whether a daily oral oil made from a full-spectrum cannabis plant extract with very low THC (FEN164) can safely help children with autism. The study will include 18 children aged 8 to 17 with moderate to severe autism (Level 2 or 3). Over 20 weeks, researchers wi…

Researchers are studying how a full-spectrum medicinal cannabis plant extract with very low THC, called NTI164, moves through the body of healthy adult volunteers. The trial measures how much of the drug reaches the bloodstream and how much leaves the body in urine over up to 28 …